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Abstract
Objectives:Mannose-binding lectin (MBL) and ficolins activate the complement cascade, which is involved in atherogenesis.
Based on a pilot study, we hypothesized that functional polymorphisms in the MBL gene (MBL2) leading to dysfunctional
protein are related to development of myocardial infarction (MI). The aim of the present study was to study polymorphisms
in MBL2 and ficolin genes in relation to the risk of MI.
Methods and Results: Using the population-based HUNT Study in Norway, 57133 persons were followed up for a first-time
MI from 1995–1997 until the end of 2008. The 370 youngest MI patients were matched by age (range 29–62 years) and
gender to 370 controls. A younger population was selected because disease in this group might be less dependent on non-
genetic risk factors. The study size was based on power calculation. Polymorphisms in MBL2 and in the genes of ficolin-1,
ficolin-2 and ficolin-3 were genotyped by pyrosequencing and related to the risk of MI, estimated as odds ratios (OR).
Functional haplotypes were analyzed and stringent alpha levels of significance were set by permutation testing. Variant
MBL2 haplotypes causing MBL deficiency were associated with a two-fold higher risk of MI (OR 2.04, 95%CI 1.29–3.24).
Adjustments for conventional cardiovascular risk factors did not substantially influence the association. The ficolins were not
associated with MI risk.
Conclusion: In a young to middle aged and relatively healthy Caucasian population, MBL2 variants related to functional MBL
deficiency were associated with a doubling of the risk for MI, independent of conventional risk factors. This supports that
MBL deficiency may lead to increased atherosclerosis or development of vulnerable plaques.
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Introduction
Accumulating evidence suggests that atherosclerosis is an
inflammatory disease where the innate immune system plays a
crucial part in the pathophysiology [1]. The complement system is
involved at different stages of atherosclerosis, from the early
formation of fatty streaks [2] until destabilization of mature
plaques. In addition to enhancing the atherosclerotic process,
activation of the complement cascade may also have a protective
effect by removing cell debris and immune complexes from the
atherosclerotic lesions.
The complement system is activated through three possible
pathways, denoted as the classic, alternative or lectin pathway.
The latter is initiated by mannose-binding lectin (MBL) or by
proteins of the ficolin family [3]. During the last decade MBL has
received attention as a potential marker of atherosclerosis. The
MBL gene (MBL2) has several polymorphic sites [4], and the
combined genetic profile corresponds to normal, intermediate or
deficient serum concentrations of the protein [5]. After the original
study by Madsen et al in 1998, where MBL deficiency was
associated with increased risk for severe atherosclerosis in relatively
young patients [6], polymorphisms in MBL2 and serum concen-
trations of the protein have been linked to both increased and
reduced risk of atherosclerosis and coronary artery disease in
different populations [7,8,9,10,11]. Furthermore, a study in
knockout mice demonstrated increased atherosclerotic lesions
when the lectin pathway was inhibited [12].
In a pilot study including patients with stable angina pectoris,
we found an increased frequency of variant MBL2 haplotypes
corresponding to MBL deficiency in patients with significant
coronary artery stenosis compared to patients without significant
stenosis, as detailed below. Based on the results from that study, we
hypothesised that MBL deficiency is related to the development of
myocardial infarction (MI) and that variations in the genes coding
for MBL and ficolins may be associated with atherosclerosis.
We therefore performed a case-control study, assessing the
association of MBL2 and ficolin genotypes with the risk of a first-
time MI at young and middle age, i.e. at an age when the genetic
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influence may be stronger and less dependent on non-genetic risk
factors than at older age. The study showed that MBL deficiency
was associated with a doubling of the risk for MI, independent of
conventional risk factors. This supports a protective role of MBL
in atherosclerosis.
Methods
Ethics statement
The study protocols conformed to the Helsinki declaration.
Both studies were approved by the Regional Research Ethics
Committee in Medicine, Central Norway (reference 157-1997
dated 06/11/1997 and reference 2009/1852-2, dated 11/20/
2009), and the case-control study was approved by the Data
Inspectorate of Norway. The participants in the pilot study gave
written informed consent. The HUNT2 participants had signed
consent to participate in morbidity and mortality follow-up studies.
No minors or children participated in the present study.
The pilot study was based on data from 236 adults (146 males
and 90 females) in a study on circulating plasma markers of
inflammation, admitted for first-time elective coronary angiogra-
phy due to suspected coronary artery disease as detailed previously
[13]. Later, data on other genetic markers in this population have
also been published [14,15]. Briefly, the patients with available
samples for the present pilot study (n = 234 due to 2 lost samples)
consisted of 131 patients with significant (.50%) artery stenosis in
at least one main coronary artery branch and 103 patients without
significant coronary artery stenosis, as demonstrated by quantita-
tive coronary angiography. Information was also registered about
classical cardiovascular risk factors (body mass index (BMI),
smoking, hypertension, hypercholesterolemia, and diabetes). DNA
was extracted from blood samples anticoagulated with ethylene-
diaminetetraacetic acid by a salting-out procedure and genotyping
for MBL2 polymorphisms was performed as described in [16].
Plasma was kept at 270uC and later analyzed for MBL
concentrations using an in-house enzyme-linked immunoassay
[17].
The case-control study was generated by linkage of population
data from the second wave of the Nord-Trøndelag Health Study
(HUNT2) to validated information on incident acute MIs.
HUNT2 was carried out in 1995–1997 as a population-based
study and information was collected through comprehensive
questionnaires and a clinical examination. The county of Nord-
Trøndelag is fairly representative for Norway as a whole, with only
3% non-Caucasians. All inhabitants 13 years of age and older
were invited, and a venous blood sample was drawn from all
persons 20 years of age and older. In total, about 75 000 (70%) of
those invited attended the study. The inclusion process is described
elsewhere [18].
There are two primary referral hospitals in the county of Nord-
Trøndelag (Levanger Hospital and Namsos Hospital). Data on all
acute MI hospitalizations from 1995 (corresponding to the
commencement of HUNT2) to the end of 2000 were registered
retrospectively, whereas from 2001 registration has been done
prospectively. MI was diagnosed according to the European
Society of Cardiology/American College of Cardiology consensus
guidelines [19]. The criteria were elevated troponin T or troponin
I at the same time course with at least one of the following criteria:
1) symptoms consistent with myocardial infarction and/or 2) ECG
changes with development of significant Q wave and/or 3) ECG
changes consistent with ischemia (ST-segment elevation or
depression).
Among participants in HUNT2, the following criteria had to be
met to be eligible for the present study: available DNA, and no
previous self-reported MI, angina pectoris or stroke. In total,
57 133 individuals met these criteria. We linked these HUNT2
participants to the hospital registrations to ascertain incident cases
of MI from baseline at HUNT2 until the end of 2008. During
follow-up, 1689 individuals had experienced an MI. Among
incident MI patients, the 370 youngest were selected as cases in the
study. As controls, we randomly selected 370 participants who
were matched to the cases by age (62 years) and gender. All
controls were at risk of MI at the time when the MI occurred in
their respective matched case.
Clinical information
Measurements of blood pressure, height, weight, waist and hip
circumference were done as previously described [18]. BMI and
waist-hip ratio (WHR) were calculated. Concentrations of blood
lipids, creatinine and glucose were analysed by standard methods
at the Central Laboratory at Levanger Hospital. Hypertension was
defined as systolic blood pressure $140 mmHg or as diastolic
blood pressure $90 mmHg, or as current use of antihypertensive
medication. Information on use of other medications, such as
statins or anti-platelet therapy was not available. Hypercholester-
olemia was defined as total cholesterol .6.2 mmol/L. Smoking
was classified in three groups: never, former or current smokers. A
report of MI before 60 years of age in first-degree relatives was
considered as a positive family history. The Framingham risk score
[20] was calculated based on the corresponding variables from the
HUNT2 database (age, HDL-cholesterol, total cholesterol, systolic
blood pressure, antihypertensive treatment, smoking and diabetes).
To classify the metabolic syndrome, a modified set of criteria
based on The International Diabetes Federation consensus [21]
were used. The criteria were 1) central obesity, (men: waist
circumference $94 cm; women: waist circumference $80 cm)
plus two of the following four criteria 2a) low HDL cholesterol (men
,1.03 mmol/L; women ,1.29 mmol/L), 2b) hypertension (systolic
blood pressure $130 mmHg or diastolic blood pressure $85 mm
Hg, or treatment for hypertension), 2c) fasting plasma glucose
$5.6 mmol/L or previously diagnosed type 2 diabetes, 2d) fasting
triglycerides .1.7 mmol/L.
Genotyping
DNA was extracted from peripheral blood leukocytes at the
HUNT biobank using a commercial kit (Puregene, Gentra
Systems, Minneapolis, MN) or by a robotic method (Autopure
LS, Gentra Systems). Genotyping was performed using a
combination of polymerase chain reaction (PCR) and pyrose-
quencing. All of the single nucleotide polymorphisms (SNPs) are
found in the online database http://www.ncbi.nlm.nih.gov/snp/.
The sequences were based on ENSG00000165471 (MBL2),
ENSG00000085265 (FCN1), ENSG00000160339 (FCN2), and
ENSG00000142748 (FCN3) in Ensemble release 65.
Four different SNPs in MBL2 were investigated (Figure 1, Panel
A). Three of them are in exon 1 and give rise to the structural
alleles B (codon 54, rs1800450), C (codon 57, rs1800451) and D
(codon 52, rs5030737). Wild type is denoted A. The fourth is
considered the most important promoter polymorphism: X/Y
(rs7096206). These SNPs are inherited in haplotypes. To simplify
the interpretation, data are presented by pooling the structural
alleles B–D to one allele denoted O [4]. The structural alleles are
always found on a Y promoter background, thus we used the term
YO to denote this defective haplotype. Combining the promoter
variant with the A and O alleles results in 6 haplotypes, as shown in
Figure 1, Panel B. These haplotypes were further combined into
three haplotype groups: normal (YA/YA, YA/XA), intermediate (XA/
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XA, YA/YO) or deficient (XA/YO, YO/YO), which correspond to
serum concentrations of functional MBL [5].
One common polymorphic site in the promoter of the ficolin-1
gene (FCN1 2542, rs10120023) was genotyped. In the ficolin-2
gene (FCN2), two amino acid substituting SNPs in exon 8 were
included. They are known to cause increased (FCN2 +6424,
rs7851696) and reduced (FCN2 +6359, rs17549193) binding
capacity of the protein to N-acetylglucosamine, respectively [22].
The gene coding for ficolin-3 (FCN3) is less polymorphic, but a
frame-shift variation in position +1637 (rs28357092) of FCN3 is
known to cause a 50% reduction of serum ficolin-3 in
heterozygotes, and total ficolin-3 deficiency in homozygotes [23].
Despite its low allele frequency, this SNP was also included.
Four different PCR reactions were set up: MBL2 exon 1, MBL2
promoter, both FCN2 SNPs, and FCN1 and FCN3 in the same
reaction. The primers are available as supporting information
(Table S1). One primer in each pair was biotinylated. Evaluation
of the PCR products by agarose gel electrophoresis showed
specific bands of the expected molecular weights. The PCR
product was further used for pyrosequencing. We chose the
pyrosequencing platform because it has been successfully used for
MBL2 genotyping [24]. Pyrosequencing was performed with a
standard protocol on Pyro sequencer PSQ 96MA (Pyrosequencing
AB; Biotage, Uppsala, Sweden), using a commercially available kit
(PyroMark Gold Q96 Reagents, Qiagen, Germany).
Statistical analyses
In the pilot study, the Chi-square test was employed to compare
the distribution of MBL2 haplotype groups between patients with
and without significant coronary artery stenosis. Logistic regres-
sion modelling was used to adjust for the classical cardiovascular
risk factors. Plasma MBL concentrations were compared among
patients with different MBL2 haplotypes using the Kruskal-Wallis
test.
Based on an expected frequency of 0.08 of the MBL2 combined
low expressing haplotype (YO/YO+XA/YO) in Caucasians, a power
calculation was performed for the case-control study. To detect an
odds ratio (OR) of 2.0, assuming a power of 80% and a 5%
significance level, 320 persons were required in each group. In
order to account for possible variations in the genotype
distribution in small datasets, 370 persons were included in each
group. The study population was too small for analyses stratified
by gender.
McNemar’s test was used to compare numbers of discordant
pairs. Due to non-normal distribution of several variables, the
Wilcoxon signed rank test was used to evaluate differences in
continuous and ordinal variables between pairs. The Kruskal-
Wallis test was used to compare serum total cholesterol, total
cholesterol – HDL cholesterol ratio, and triglycerides within the
MBL2 haplotype groups. The Chi-square test was used for
comparison of allele frequencies and of frequencies of participants
with hypercholesterolemia within the MBL2 haplotype groups.
Deviation from the Hardy-Weinberg equilibrium was calculated
by using the chi-square test.
Conditional logistic regression was performed to evaluate
associations between the three inferred MBL2 haplotype groups
and risk of MI. Further models were developed, where traditional
risk factors (hypertension, hypercholesterolemia, smoking, diabetes
and BMI (continuous)), the Framingham risk score or the
metabolic syndrome were also included.
All tests were two-sided and the results are presented as means,
ORs or HRs (with 95% confidence intervals (CI)). To avoid false
positive conclusions, the alpha level of significance for the
comparisons of haplotype frequencies between cases and controls
were obtained by permutation testing, using 10,000 permutations.
By this method, which is considered the gold standard, a result is
significant if the observed p-value is lower than the empirical p-
value found under permutation. For other tests, p-values below
0.05 were considered statistically significant. Pilot data was
analysed with SPSS for Windows, version 19.0.0 (IBM, New
York, USA). Permutation testing was performed using the R
package, version 2.14.1 (http://www.r-project.org). All other
analyses were performed with Stata/MP for Mac, version 11.2,
(Stata Corp., College Station, Texas, USA).
Results
In the pilot study, male gender, smoking and hypercholester-
olemia were more frequent among the patients with significant
coronary artery disease [13]. There was an increased frequency of
the low MBL2 haplotype group among patients with significant
coronary artery stenosis (p = 0.050, Table 1). The association
remained after adjustment for classical risk factors (p = 0.052). As
found in previous studies [5], plasma MBL concentrations
corresponded closely to the haplotype groups (p,0.0001, Table 1).
Background characteristics of MI cases and their matched
controls are displayed in Table 2. Among cases, baseline
measurements of conventional risk factors indicated higher risk
of MI in cases than controls: cases had higher BMI, WHR,
Framingham risk score and a more unfavourable lipid profile.
Furthermore hypertension, diabetes, current smoking, the meta-
bolic syndrome and family history of MI were also more frequent
among cases. Creatinine concentrations were similar in the two
groups, and were below 140 mmol/L in all participants, indicating
Figure 1. MBL2 gene and haplotypes. Panel A: Simplified figure of the investigated MBL2 polymorphisms. Wild type allele is A. Panel B: MBL2
haplotypes and corresponding concentrations of functional MBL.
doi:10.1371/journal.pone.0042113.g001
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no severe chronic renal failure. Mean age at MI was 53 years
(range 29–62 years).
There were no significant deviations from the expected Hardy-
Weinberg distributions in the control group (for structural alleles,
p = 0.39). Frequencies of MBL2 haplotypes are given in Table 3.
There were higher frequencies of variant haplotypes causing MBL
deficiency among cases, compared to controls (p = 0.025, alpha
level by permutations = 0.028). Ficolin genotypes are shown in
Table 4. There were no significant differences between cases and
controls. For FCN1 2542, however, the number of homozygous
individuals was higher in the control group (p = 0.07, recessive
model). Frequencies of MBL2 and ficolin alleles are available as
supporting information (Table S2 and Table S3).
Conditional logistic regression showed that variant MBL2
haplotypes causing MBL deficiency were positively associated
with MI (Table 5). The three haplotype groups, corresponding to
functional MBL concentration, were used in the analyses. The
odds for MBL deficiency among MI cases was twice as high as in
controls (OR = 2.04, 95%CI 1.29–3.24, p = 0.003), and adjust-
ment for conventional cardiovascular risk factors (hypertension,
BMI, hypercholesterolemia, diabetes, and smoking, OR 2.02,
95%CI (1.17–3.47), p = 0.012), the Framingham risk score, or
presence/absence of the metabolic syndrome did not substantially
influence the association (Table 5). There was missing data on
family history in 131 case-control pairs (71 cases and 66 controls,
p = 0.64), and information on family history was therefore not
included in the analysis. There were no associations between lipid
profile and MBL2 haplotypes (total cholesterol: cases p = 0.66,
controls p = 0.43; total cholesterol – HDL cholesterol ratio: cases
p = 0.68, controls p = 0.14; triglycerides: cases p = 0.69, controls
p = 0.16; frequency of hypercholesterolemia: cases p = 0.28,
controls p = 0.60).
Discussion
In this population-based case-control study we found that
variant MBL2 haplotypes causing MBL deficiency were associated
with a doubling of the risk of MI at middle age (before the age of
62 years). The association was independent of conventional risk
factors for MI. Based on the pilot study where associations among
variant MBL2 haplotypes, low plasma concentrations of MBL, and
increased frequency of significant coronary artery stenosis were
demonstrated, increased atherosclerosis is a probable explanation
of this finding.
Previous studies support our finding. However, those studies
were performed among patients with severe atherosclerosis [6] or
other predisposing conditions, such as a high prevalence of
coronary artery disease [7] or inflammatory diseases, i.e. systemic
lupus erythematosus [11], rheumatoid arthritis [25] or type 2
diabetes mellitus. Our results also suggest that MBL deficiency is a
particularly strong risk factor for cardiovascular events among
young to middle-aged and apparently healthy individuals.
Although the study population was relatively young, conven-
tional cardiovascular risk factors, including hypertension, hyper-
cholesterolemia, smoking and high BMI were also associated with
increased risk of MI. Despite incomplete data, there was also a
positive association of family history of MI with MI risk. We chose
to study people at middle age, anticipating that underlying causes
of an early MI would be more likely to be genetic compared to an
older age, when non-genetic causes may dominate. Another
reason was our previous finding that MBL2 was more strongly
associated with severe atherosclerosis in the youngest patients
going through coronary surgery [6]. At older age, the importance
of genetic factors may be difficult to distinguish from the impact of
environmental and life style factors and comorbidities.
Table 1. Data on MBL2 haplotypes and MBL plasma concentrations from the pilot study.
MBL2 haplotype
Coronary artery stenosis YA/YA, YA/XA XA/XA, YA/YO XA/YO, YO/YO p-value
No (103) 57 (55%) 36 (35%) 10 (10%)
Yes (131) 75 (56%) 31 (23%) 25 (19%) 0.05
MBL plasma concentration (mg/L) 1797 (1618–1976) 373 (289–456) 13 (1–25) ,0.0001
doi:10.1371/journal.pone.0042113.t001
Table 2. Baseline characteristics.
Cases Controls p-value
(n =370) (n =370)
Gender, female/male 88/282 ---
Age, years 48 (47–48) ---
BMI*, kg/m2 27.4 (27.0–27.8) 26.5 (26.1–26.9) 0.003
WHR{ 0.89 (0.88–0.90) 0.88 (0.87–0.89) 0.011
Hypertension 194 (52%) 162 (44%) 0.015
Systolic blood pressure 140 (139–142) 136 (135–138) 0.002
Diastolic blood pressure 85 (84–86) 83 (82–84) 0.003
Hypercholesterolemia 242 (65%) 146 (39%) ,0.0005
Diabetes mellitus 13 (4%) 4 (1%) 0.049
Total cholesterol, mmol/L 6.8 (6.6–6.9) 6.0 (5.9–6.2) ,0.0005
Triglycerides, mmol/L 2.53 (2.35–2.70) 2.05 (1.91–2.18) ,0.0005
HDL cholesterol, mmol/L
Women 1.37 (1.29–1.45) 1.49 (1.40–1.58) 0.024
Men 1.13 (1.08–1.17) 1.22 (1.18–1.26) ,0.0005
Smoking
Never 68 (19%) 114 (32%)
Former 67 (18%) 81 (23%)
Current 228 (63%) 156 (44%) ,0.0005
Framingham risk score
Women 13.1 (12.0–14.2) 9.3 (8.1–10.5) ,0.0005
Men 13.4 (13.0–13.9) 11.6 (11.1–12.1) ,0.0005
Metabolic syndrome 37 (10%) 20 (5%) 0.022
Family history{ 100 (27%) 54 (15%) 0.001
*Body mass index (BMI).
{Waist hip ratio (WHR).
{Myocardial infarction before 60 years in first-degree relatives.
doi:10.1371/journal.pone.0042113.t002
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Previous studies support a cardio-protective role of MBL [26]
and activation of the lectin pathway. Rats with MBL deficient
macrophages fed on a high-cholesterol diet were more likely to
develop atherosclerotic lesions, which may be explained by
reduced removal of apoptotic cells and debris by MBL [12].
Remaining apoptotic cells may then increase inflammation and
lead to formation of vulnerable plaques, which can result in MI,
independent of the extent of atherosclerotic disease. In humans,
variant MBL2 alleles may be correlated with increased carotid
plaque area [9] and MBL deficient individuals may also have
higher postprandial lipid values [27], which in turn may contribute
to the development of atherosclerosis [28]. In our study, we did
not observe any association between lipid values and MBL2
haplotypes. Although the link between infections and atheroscle-
rosis is not verified, a combination of MBL deficiency and
infection was related both to the development of coronary artery
disease [8] and to reduced flow-mediated vasodilation [29], which
is an early marker of endothelial dysfunction. Those results imply
plausible mechanisms that may contribute to an increased risk of
atherosclerosis in the presence of MBL deficiency.
On the other hand, others have found that high serum MBL-
concentrations [10] and wild type MBL2 may be associated with
increased risk of cardiovascular disease. A dual effect of MBL has
been suggested, as both high and low serum concentrations of
MBL were correlated with increased intima-media thickness of the
Table 3. Haplotype frequencies for MBL2.
MBL2 genotypes MBL2 haplotypes MBL2 recessive model
Cases Controls Cases Controls Cases Controls
YA/YA 112 (30%) 117 (32%)
YA/XA 86 (23%) 100 (27%) 198 (54%) 217 (59%)
XA/XA 18 (5%) 12 (3%)
YA/YO 91 (25%) 108 (29%) 109 (29%) 120 (32%) 307 (83%) 337 (91%)
XA/YO 43(12%) 24 (7%)
YO/YO 20 (5%) 9 (2%) 63 (17%) 33 (9%) 63 (17%) 33 (9%)
p-value 0.025 0.005 0.001
Alpha level by permutation 0.028 0.023 0.029
doi:10.1371/journal.pone.0042113.t003
Table 4. Genotype frequencies for FCN1, FCN2 and FCN3.
Cases Controls p-value
FCN1 -542 G/A
G/G 148 (40%) 137 (37%)
G/A 177 (48%) 170 (46%)
A/A 45 (12%) 63 (17%) 0.19*
FCN2 +6359 C/T
C/C 181 (49%) 196 (53%)
C/T 157 (42%) 141 (38%)
T/T 32 (9%) 33 (9%) 0.46
FCN2 +6424 G/T
G/G 289 (78%) 295 (80%)
G/T 77 (21%) 71 (19%)
T/T 4 (1%) 4 (1%) 0.86
FCN3 +1637 C/2 {
C/C 363 (99%) 364 (99%)
C/2 5 (1%) 4 (1%)
2/2 0 (0%) 0 (0%) 0.74
*FCN1 recessive model: p = 0.069.
{4 missing.
doi:10.1371/journal.pone.0042113.t004
Table 5. Conditional logistic regression analyses, MBL2
functional groups.
OR 95% CI p-value
Model 1
YA/YA, YA/XA 1
XA/XA, YA/YO 1.01 (0.72–1.41) 0.96
XA/YO, YO/YO 2.04 (1.29–3.24) 0.003
Model 2*
YA/YA, YA/XA 1
XA/XA, YA/YO 1.02 (0.73–1.44) 0.89
XA/YO, YO/YO 1.91 (1.19–3.08) 0.008
Model 2 – Adjusted for classical risk factors* {
YA/YA, YA/XA 1
XA/XA, YA/YO 1.26 (0.84–1.88) 0.27
XA/YO, YO/YO 2.02 (1.17–3.47) 0.012
Model 2 – Adjusted for Framingham risk score* {
YA/YA, YA/XA 1
XA/XA, YA/YO 1.19 (0.80–1.77) 0.39
XA/YO, YO/YO 2.09 (1.22–3.59) 0.007
Model 3 – Adjusted for metabolic syndrome 1
YA/YA, YA/XA 1
XA/XA, YA/YO 1.06 (0.76–1.49) 0.73
XA/YO, YO/YO 1.98 (1.25–3.16) 0.004
*26 pairs excluded because one or more missing values.
{Adjusted for classical risk factors: Hypertension (BP.140/90 or current use of
antihypertensive medication), body mass index (kg/m2, continuous),
hypercholesterolemia (total cholesterol .6.2 mmol/L), diabetes (yes/no) and
smoking (never/former/current).
{Adjusted for Framingham risk score (age, HDL-cholesterol, total cholesterol,
systolic blood pressure, smoking and diabetes).
13 pairs excluded because one or more missing values.
doi:10.1371/journal.pone.0042113.t005
Mannose-Binding Lectin and Myocardial Infarction
PLOS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e42113
carotid artery in persons with rheumatoid arthritis [25]. Speidl et
al have suggested that activation of the complement cascade by the
alternative pathway may be proatherogenic as a result of
inflammation, whereas activation through the lectin and classical
pathways may have protective effects [30]. Activation of the lectin
pathway of complement through MBL and MBL-associated serine
proteases may activate the coagulation cascade and lead to
thrombosis [31] which could increase the risk of MI. Furthermore,
it should be noted that MBL and activation of the lectin pathway
appears to be central in ischemic reperfusion injury, which may
blur the relative cardioprotective effects of MBL in atherosclerosis
[32,33]. Thus, current evidence indicates that MBL has several
effects that either may increase or reduce the risk of cardiovascular
events, and the clinical importance in different settings is not fully
understood
Analysis of haplotypes with known functional consequences and
ensuring stringent alpha levels of significance by permutation
testing strengthen the probability of a causal relationship, even if
the design of our study did not allow direct causal inference. Our
results corroborate that genetically determined MBL deficiency is
linked to atherosclerosis. However, we cannot exclude that high
MBL concentration and an ‘‘eager’’ complement system may also
be harmful in the atherosclerotic process under some circum-
stances.
None of the ficolin polymorphisms were significantly related to
MI. One may speculate that being homozygous for FCN1 2542
yields some protection, but little is known about the effects of this
genetic variation, and more research is needed.
This study was not designed to test improvement of risk
prediction. However, the results may generate new hypotheses
regarding pathophysiology.
Study Limitations
There are some limitations to our study. MBL2 haplotypes were
not assessed in all MI patients from the HUNT2 study; hence it is
not known whether the associations are present in older
individuals. Serum was not available at the time of the genotyping.
However, our pilot study and other previous studies have shown
that serum concentrations of functional MBL correspond closely to
the genotypes [5]. The risk for an early MI is also influenced by
other genetic factors, which were not included in the present study.
Non-linearity in the light response following incorporation of more
than five nucleotides may play a role in the assessment of
homopolymeric regions like the one in FCN3. All samples with
uncertain results were therefore re-sequenced manually. The
results were not replicated in a similar cohort, as they were partly
confirmatory. Because the included polymorphisms are located
closely together and are not covered in previously published
genome-wide association studies on early MI, it was not possible to
use such data for replication. Although the population in Norway
is assumed to be generally representative for the Caucasian
population, we cannot exclude the possibility that MBL may be
more important in relation to cardiovascular disease in this
population compared to others.
Conclusions
The MBL2 haplotypes corresponding to functional MBL
deficiency were associated with a doubling of the risk for MI in
individuals younger than 62 years of age, independent of
conventional risk factors. The findings confirm our hypothesis
and support that MBL deficiency may lead to increased
atherosclerosis or development of vulnerable plaques.
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